Edition:
United States

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

14.16USD
25 May 2017
Change (% chg)

$-0.08 (-0.56%)
Prev Close
$14.24
Open
$14.28
Day's High
$14.40
Day's Low
$13.92
Volume
41,483
Avg. Vol
90,278
52-wk High
$19.10
52-wk Low
$7.14

CNCE.OQ

Chart for CNCE.OQ

About

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform... (more)

Overall

Beta: --
Market Cap(Mil.): $319.49
Shares Outstanding(Mil.): 22.56
Dividend: --
Yield (%): --

Financials

  CNCE.OQ Industry Sector
P/E (TTM): -- 138.86 17.42
EPS (TTM): -2.25 -- --
ROI: -47.34 2.17 -5.45
ROE: -51.92 0.04 -4.73

BRIEF-Concert pharmaceuticals announces shareholder approval of CTP-656 asset purchase agreement with Vertex Pharmaceuticals

* Concert pharmaceuticals announces shareholder approval of CTP-656 asset purchase agreement with Vertex Pharmaceuticals

May 24 2017

BRIEF-Vertex Pharmaceuticals says FTC requested for additional information on pending acquisition from Concert Pharmaceuticals

* Vertex Pharmaceuticals says on May 19, the U.S. FTC issued a request for additional information in connection co's pending acquisition of CTP-656 and other assets from Concert Pharmaceuticals

May 22 2017

BRIEF-Concert Pharmaceuticals receives second request from FTC under Hart-Scott-Rodino Act

* Concert Pharmaceuticals receives second request from FTC under Hart-Scott-Rodino Act

May 22 2017

FDA places clinical hold on Concert Pharma's hair loss drug

Concert Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration (FDA) imposed a clinical hold on a trial testing the company's drug to treat alopecia areata, a type of hair loss.

May 17 2017

UPDATE 3-FDA places clinical hold on Concert Pharma's hair loss drug

* Analyst does not expect long delay in trial (Adds analyst comment, updates shares)

May 17 2017

FDA places clinical hold on Concert Pharma's hair loss drug

May 17 Concert Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration imposed a clinical hold on a mid-stage trial testing the company's drug to treat alopecia areata, a type of hair loss.

May 17 2017

BRIEF-FDA puts clinical hold on Concert Pharma's hair loss drug

* Concert Pharmaceuticals announces clinical hold on ctp-543 phase 2A trial

May 17 2017

BRIEF-Concert Pharmaceuticals Q1 loss $0.60/shr

* Concert pharmaceuticals reports first quarter 2017 financial results

May 02 2017

BRIEF-Concert Pharmaceuticals initiates CTP-543 phase 2 trial in alopecia areata

* Concert Pharmaceuticals initiates ctp-543 phase 2 trial in alopecia areata

May 02 2017

BRIEF-Concert Pharmaceuticals says announced an unexpected delay in initiation of CTP-543 phase 2a trial

* Concert Pharmaceuticals Inc - announced an unexpected delay in initiation of CTP-543 phase 2a trial for alopecia areata

Apr 05 2017

More From Around the Web

Earnings vs. Estimates